Monday, June 6, 2016
Quintiles, the world’s largest provider of biopharmaceutical services, has introduced a new patient enrollment offering designed to accelerate study startup and reduce costs for oncology clinical trials by opening investigative sites for studies only after they have identified a qualified patient.
Amulet Capital Partners, a middle-market private equity investment firm based in Greenwich, Connecticut, focused exclusively on the healthcare sector, has acquired SynteractHCR Holdings, a CRO focused on phase I‐IV clinical trials for emerging to mid-sized biopharma clients in the U.S., Europe and Asia. Terms of the transaction were not disclosed.
INC Research Holdings, a global phase I to IV CRO, has announced the relocation and expansion of its Osaka, Japan office in support of the company’s long-term growth strategy both in Japan and across the Asia/Pacific region.
With an improving Spanish pharmaceutical market, ClinTec International has identified the country as a target market for expansion. Following a year of steady growth by ClinTec’s Spain-based team, the global CRO is capitalizing on the improving Spanish economy by opening two new offices, and creating a new regional manager position, which will oversee both Spanish and Portuguese markets.
Thermo Fisher Scientific has announced an acquisition of FEI, a provider of high-performance electron microscopy, for $107.50 per share in cash. The transaction represents a purchase price of approximately $4.2 billion.
ClinTec International is expanding, opening two new offices in Spain, and appointing Carlos Palacios as the company’s new regional manager for Spain and Portugal.
BioPharma Services USA has been awarded a five-year, $20 million contract with the Center for Drug Evaluation and Research (CDER), a division of the FDA. The contract is to conduct in vivo studies of generic drug products in human subjects over a period of five years, from 2016 through to 2021.
KMR Group, a provider of biopharmaceutical R&D performance analytics, has announced its newest online clinical trial performance application, CRO Metrix. The tool helps clinical research organizations and sponsor biopharmaceutical companies assess the performance of CROs.
PSI, a global full-service CRO, is opening a new office in Durham, North Carolina, in the region known as Research Triangle Park (RTP). The new office is in addition to the PSI operational offices in King of Prussia, Pennsylvania, and San Francisco, California.